Innovative Bispecific Nanobody Targeting CD274 and CXCR4 for Pancreas Cancer Immunotherapy

VHH-P835 is a bispecific, humanized nanobody designed to target both CD274 molecule (CD274) and C-X-C motif chemokine receptor 4 (CXCR4). Engineered for optimal binding, this nanobody leverages distinct immunological pathways to tackle the complex tumor microenvironment of pancreas cancer. Currently in the Biological Testing stage, VHH-P835 holds significant promise for the treatment of pancreas cancer by interfering with key mechanisms that contribute to immune evasion and tumor progression. Its unique dual specificity positions it as a promising therapeutic candidate in the evolving landscape of oncology.

Licensing Opportunity

VHH-P835 is available for out-licensing and partnership opportunities. We welcome inquiries from pharmaceutical and biotechnology companies interested in advancing this bispecific nanobody into further development and clinical application.

Development Phase

Modality

VHH-P835 is constructed as a bispecific nanobody featuring two single-domain antibody fragments (VHH), each targeting a different key molecule involved in tumor biology. These domains are connected by a flexible (G4S)3 linker, allowing simultaneous engagement of both targets. As a single-domain antibody, VHH-P835 is characterized by its small molecular size and robust stability, which enable superior tumor tissue penetration and improved pharmacokinetics compared to traditional monoclonal antibodies. These structural advantages support the effective delivery of therapeutic activity within the dense stromal environment typical of pancreas cancer, addressing challenges often encountered by larger antibody therapeutics.

Target

CD274 and CXCR4 are pivotal molecular targets in the tumor microenvironment. CD274, known as an immune checkpoint protein, regulates T-cell activity and contributes to immune escape mechanisms in cancer. CXCR4 is a chemokine receptor implicated in tumor cell migration, metastasis, and interaction with the stroma. Both CD274 and CXCR4 are broadly expressed in pancreatic tumor cells and the surrounding immune milieu. Dual targeting of CD274 and CXCR4 in pancreas cancer is supported by accumulating scientific evidence that disrupting these pathways can restore anti-tumor immunity and inhibit metastatic dissemination. VHH-P835’s ability to bind both CD274 and CXCR4 highlights its strategic value as a next-generation therapeutic.

Mechanism of Action

VHH-P835 exerts its anti-tumor effects through dual mechanisms. By targeting CD274, it disrupts immune checkpoint signaling, lifting the brakes on T-cell activity and enhancing anti-cancer immune responses. Simultaneously, binding to CXCR4 interferes with the SDF-1/CXCR4 axis, which is critical for cancer cell migration, invasion, and the formation of a pro-tumoral stroma. The combined inhibition of these pathways has the potential to synergistically boost immune-mediated tumor clearance and prevent metastatic progression. Moreover, the nanobody format of VHH-P835 enables future adaptation for multivalent, bispecific, or conjugated therapeutic modalities, broadening its application across diverse immuno-oncology strategies.

Pancreas Cancer

Pancreas cancer is a highly lethal malignancy with a rising global incidence and poor long-term survival rates. This condition is characterized by late diagnosis, early metastasis, and limited responsiveness to conventional therapies. Current treatment options include surgery, chemotherapy, and targeted therapies, but most patients present with advanced disease that is unresectable, resulting in a high mortality rate. Despite advances in therapeutic development, significant unmet medical needs remain due to resistance mechanisms and the immunosuppressive tumor microenvironment. Novel approaches targeting immune evasion and metastatic pathways are urgently required. VHH-P835, by addressing both CD274 and CXCR4, offers an innovative solution with the potential to overcome current clinical barriers, making it a valuable candidate in the evolving treatment paradigm for pancreas cancer.